ClinicalTrials.gg
RecruitingNCT06144593INTERCARBUpdated Nov 16, 2026

The Metabolic Impact of Intermittent Carbohydrate Restriction in Individuals With Type 2 Diabetes

An interventional study of Dietary macronutrient composition in Diabetes Mellitus, Type 2, Overweight and Obesity and Metabolic Syndrome, sponsored by Hvidovre University Hospital. Recruiting at 1 site in Denmark. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Hvidovre University Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Nov 16, 2026Primary completion movedStudy completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Diabetes Mellitus, Type 2 by Hvidovre University Hospital — 1 open to participants now, 1 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Hvidovre University Hospital.

Started
2024
the only one that year
No phase
7 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Diabetes Mellitus, Type 2 by Hvidovre University Hospital, this one is the only one that started in 2024, is one of 7 with no phase, and was the 12th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 12 studies in Diabetes Mellitus, Type 2 by Hvidovre University Hospital is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Diabetes Mellitus, Type 2 by Hvidovre University Hospital, or all of them as a file.
02

Study summary

The primary aim of this randomized cross-over intervention study is to investigate the effect of 16 days of intermittent carbohydrate restriction (alternating between two days of a conventional control diet and, two days of carbohydrate restriction to 10E% (\~70-90 grams)) on 24-hour average sensor glucose (primary outcome) in individuals with type 2 diabetes compared with a 16 day control period with a conventional diet. 24-hour average sensor glucose is measured by patient-blinded continuous glucose monitoring (CGM) during the intervention and control period.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Overweight and Obesity
  • Metabolic Syndrome
  • Nutrition

Keywords

  • Diet
  • Nutrition
  • Type 2 Diabetes
  • Metabolic Syndrome
  • Obesity
  • Glucose Homeostasis
04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women
  • 35-75 years old
  • >27 kg/m2
  • Known type 2 diabetes in stable glucose lowering therapy (for three months) or with >48 mmol/mol if no glucose lowering therapy

Exclusion criteria

Exclusion criteria:

  • Anemia ( \<8 mmol/L for men and \<7 mmol/L for women)
  • Thyroid disease if not well controlled based on patient reporting and/or the most recent measurement of TSH.
  • Treatment with insulin or sulfonylurea
  • Treatment with systemic
  • Severely dysregulated diabetes defined by >70 mmol/mol
  • Kidney failure ( \<30 ml/min/1.73 m²) based on patient reporting and/or the most recent control measurement.
  • History of advanced liver fibrosis or cirrhosis
  • Food allergies (including lactose and gluten intolerance)
  • Vegetarian/vegan diet or following of specific dietary plans
  • Alcohol consumptions >84/168 g/week (women/men)
  • Strenuous activity level > 120 minutes per week
  • Weight loss (>5 kg) within the last three months or previous bariatric surgery
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
11 participants (estimated)

Study arms

  • Experimental
    Intermittent carbohydrate restriction

    16 days of intermittent carbohydrate restriction: a controlled dietary regime alternating between two days of restricting carbohydrate intake to 70-90 grams, and two days of a conventional control diet. Protein content is matched between diets. All food is provided.

    Other: Dietary macronutrient composition

  • No intervention
    Control arm

    During the control period (16 days) the macronutrient composition matches that of the non-carbohydrate-restricted days of the intermittent carbohydrate intervention.

Interventions

  • OtherDietary macronutrient composition

    Intermittent carbohydrate restriction

06

What researchers measure

Primary outcomes

  1. 24-hour average sensor glucose

    A patient-blinded continuous glucose monitoring (CGM) is worn during the 16 day intervention and control period.

    Time frame: 24-hour average sensor glucose is measured as the average of eight consecutive days (starting from two days post sensor mounting).

Secondary outcomes

  1. Fasting plasma concentrations of triacylglycerols

    Fasting plasma concentrations of triacylglycerols measured on the day before and the day after the dietary intervention (i.e. day 0 and day 18) and on the day before and the day after the control period (i.e. day 0 and day 18).

    Time frame: day 18 adjusted for baseline

Other outcomes

  1. Explorative outcomes - Questionnaires on quality of life

    Participants will complete the questionnaires 'Problem Areas In Diabetes' \& 'World Health Organisation-Five Well-Being Index'.

    Time frame: day 18

  2. Explorative outcomes - Qualitative evaluation to assess feasibility of the dietary strategy

    A semi-structured evaluation interview to assess social context, eating practices, compliance to, and feasibility and acceptability of the intermittent carbohydrate restriction regime will be carried out.

    Time frame: day 18

07

Study locations

1 of 1 sites recruiting
  • Department of Endocrinology, Hvidovre Hospital
    Hvidovre, 2650, Denmark
    Recruiting
    • Kirstine Nyvold Bojsen-Møller, MD, PhD · Contact
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2027, 46 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 46 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Sep 2025 → Dec 2027 and completion Sep 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2023
First posted
Nov 22, 2023
StartActual
Jan 3, 2024
Primary completionEst.
Dec 1, 2027was Sep 2025
CompletionEst.
Dec 1, 2027was Sep 2025
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 1, 2025→Dec 1, 2027
Nov 16, 2026
Study completion
Sep 1, 2025→Dec 1, 2027
Nov 16, 2026
Enrollment
14→11
Nov 16, 2026
Eligibility
2 exclusion criteria edited, 3 added, 4 removed
What changed in the criteria
Exclusion criteria
  • RemovedTSH outside reference range
  • AddedThyroid disease if not well controlled based on patient reporting and/or the most recent measurement of TSH.
  • EditedTreatment with insulin, sulfonylurea, or SGLT2-inhibitorssulfonylurea
  • EditedSeverely dysregulated diabetes defined by HbA1c >70 mmol/mol
  • RemovedeGFR <60 ml/min/1.73 m2
  • RemovedContraindications for MR-scan: abdominal height exceed limitations of the MR-scanner, pacemaker or other electronic device implanted, implanted metal devices, severe claustrophobia
  • AddedKidney failure (eGFR <30 ml/min/1.73 m²) based on patient reporting and/or the most recent control measurement.
  • AddedHistory of advanced liver fibrosis or cirrhosis
  • RemovedHigh risk of fibrosis of the liver (estimated by FIB4 score > 3.25)
Nov 16, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frame24-hour average sensor glucose24-hour average sensor glucose is measured as the average of eight consecutive days (starting from two days post sensor mounting) from the intermittent carbohydrate restriction period and the corresponding days of the control period (i.e. days 17-24). → 24-hour average sensor glucose is measured as the average of eight consecutive days (starting from two days post sensor mounting).
  • Description24-hour average sensor glucose: how it is measured was reworded
Nov 16, 2026
Secondary outcomes
3 time frame changed, 1 removed, 1 description edited
What changed in the outcomes
  • RemovedLiver triacylglycerol contentTime frame: day 30 adjusted for baseline
  • Time frameFasting plasma concentrations of triacylglycerolsday 30 adjusted for baseline → day 18 adjusted for baseline
  • DescriptionFasting plasma concentrations of triacylglycerols: how it is measured was reworded
  • Time frameother outcomeExplorative outcomes - Questionnaires on quality of lifeday 30 → day 18
  • Time frameother outcomeExplorative outcomes - Qualitative evaluation to assess feasibility of the dietary strategyday 30 → day 18
Nov 16, 2026
Contact
Study contact's phone or email changed: a•••@regionh.dk→a•••@sund.ku.dk. See the current contact
Nov 16, 2026
Sponsor
Collaborators removed: Danish Research Centre for Magnetic Resonance
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary completion Sep 1, 2025→Dec 1, 2027
    Study completion Sep 1, 2025→Dec 1, 2027
    Enrollment 14→11
    Eligibility 2 exclusion criteria edited, 3 added, 4 removed
    What changed in the criteria
    Exclusion criteria
    • RemovedTSH outside reference range
    • AddedThyroid disease if not well controlled based on patient reporting and/or the most recent measurement of TSH.
    • EditedTreatment with insulin, sulfonylurea, or SGLT2-inhibitorssulfonylurea
    • EditedSeverely dysregulated diabetes defined by HbA1c >70 mmol/mol
    • RemovedeGFR <60 ml/min/1.73 m2
    • RemovedContraindications for MR-scan: abdominal height exceed limitations of the MR-scanner, pacemaker or other electronic device implanted, implanted metal devices, severe claustrophobia
    • AddedKidney failure (eGFR <30 ml/min/1.73 m²) based on patient reporting and/or the most recent control measurement.
    • AddedHistory of advanced liver fibrosis or cirrhosis
    • RemovedHigh risk of fibrosis of the liver (estimated by FIB4 score > 3.25)
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frame24-hour average sensor glucose24-hour average sensor glucose is measured as the average of eight consecutive days (starting from two days post sensor mounting) from the intermittent carbohydrate restriction period and the corresponding days of the control period (i.e. days 17-24). → 24-hour average sensor glucose is measured as the average of eight consecutive days (starting from two days post sensor mounting).
    • Description24-hour average sensor glucose: how it is measured was reworded
    Secondary outcomes 3 time frame changed, 1 removed, 1 description edited
    What changed in the outcomes
    • RemovedLiver triacylglycerol contentTime frame: day 30 adjusted for baseline
    • Time frameFasting plasma concentrations of triacylglycerolsday 30 adjusted for baseline → day 18 adjusted for baseline
    • DescriptionFasting plasma concentrations of triacylglycerols: how it is measured was reworded
    • Time frameother outcomeExplorative outcomes - Questionnaires on quality of lifeday 30 → day 18
    • Time frameother outcomeExplorative outcomes - Qualitative evaluation to assess feasibility of the dietary strategyday 30 → day 18
    Sponsor Collaborators removed: Danish Research Centre for Magnetic Resonance
    Contact Study contact's phone or email changed: a•••@regionh.dk→a•••@sund.ku.dk. See the current contact
    + 6 other changes: index terms, verification date, description, conditions, arm descriptions and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06144593
Responsible party
Kirstine Nyvold Bojsen-Moeller (MD, PhD, Associate Professor, Hvidovre University Hospital) — Principal investigator
First posted
Nov 22, 2023
Start date
Jan 3, 2024
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Amanda Schaufuss, MSc
Contact
amanda.schaufuss@sund.ku.dk
+4530270261

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion